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Abstract
Many candidate biomarkers for diagnosis of prostate cancer have been investigated, but prostate-specific antigen (PSA) 
testing remains the frontline test for both mass screening and individual clinical testing. Although the PSA test is 
cost-effective, analytically reliable, and flexibly high throughput, it has a very weak correlation with prostate malignancy. 
This has resulted in over-diagnosis and over-treatment of patients leading to costly economic, social, and psychological 
impacts. PSA testing lacks the ability to molecularly characterize prostate diseases and define aggressiveness and 
lethality, which are necessary to influence choice of treatment. Therefore, newer molecular tests are beginning to 
replace the PSA tests. The prostate cancer antigen 3 test has shown superiority and is now widely used. The recently 
reported sarcosine urine test, the already delineated TMPRSS2: ETS fusion genes, the glutathione-S-transferase P1 
serum marker, and enhancer of zeste homolog 2 biomarker may also help improve diagnosis and prognostication of 
prostate cancer. The analytical trend is toward a multiplex testing format using molecular and/or proteomic techniques 
that are reliable, accurate, reproducible, and ensure rapid quantitation. Therefore, validation of these newer biomarkers 
and their assays are necessary for both large-scale clinical trials and clinical utility.
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Introduction
Recently, six new candidate biomarkers for diagnosis 
of prostate cancer were reported:[1] sarcosine, uracil, 
kynurenine, glycerol‑3‑phosphate, leucine, and proline. 
Sarcosine, an N‑methyl derivative of the amino acid, 
glycine, was shown to have a very strong correlation 
with prostate cancer progression and can be detected 
non‑invasively using post‑digital rectal examination (DRE) 
in urine samples of patients. Prior to the report of sarcosine 
test, a molecular test, the prostate cancer antigen 3 (PCA3) 
assay, received its European conformity mark (CE mark), 
and is now used in many clinical laboratories across Europe 
to facilitate diagnosis of prostate cancer.[2‑6] The PCA3 test, 
which is based on a non‑coding RNA profoundly expressed 
in prostate tumours compared to benign cells, also uses 
exfoliated urinary cells after attentive DRE.[2] Since the 
clinical introduction of the PCA3 testing, several studies 
have compared its diagnostic and prognostic values to those 
of the prostate specific antigen (PSA) test for prostate 
cancer (PCa) management.[4,7‑15] The key comparator for 
all these developments remains the prostate biopsy and 
histology reports.[16] The standard method of collecting 
prostate biopsy, the transrectal ultrasound (TRUS)‑guided 
biopsy of 6‑18 prostate cores in a patient is, without 
equivocation, also prone to sampling errors.[17] In the past, 
the typical clinical strategy for diagnosis of prostate diseases 
was the triad of serum PSA test, DRE, and histology of 
prostate biopsy. In this strategy, the PSA assay was the most 
widely used but also the most controversial test. It is easily 
conducted in clinical laboratories as an enzyme‑linked 
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immunosorbent assay (ELISA) with few analytical 
limitations, and the PSA ELISA test can detect as low as 
0.3 ng/ml of PSA in serum/plasma, but its use in prostate 
cancer management has many diagnostic pitfalls.
One of the problems of the PSA testing is that the 
biomarker itself has a weak correlation with prostate 
malignancy [Figure 1]; it is copiously produced by normal 
prostatic cells. Since its discovery in the 1970s, PSA testing 
has been widely used for early detection and monitoring 
of prostate disease. But it is never used as a one‑off test. 
Critics of PSA testing believe that it has resulted in a huge 
increase in the number of prostate biopsies performed 
in histopathology laboratories; most of which (the PSA 
informed prostate biopsies) have only a 30% chance of 
detecting prostate cancer.[17] Both the PSA test and the 
“the reference standard test” (prostate biopsy) are imperfect. 
Moreover, the trauma, psychological and economic impacts 
on patients and workload on pathology laboratories of a 
negative prostate biopsy result following a raised serum 
PSA level (PSA informed prostate biopsy) is a source of 
major concern. Advocates of PSA testing can point to 
the fact that it has increased the rate of PCa detection to 
about 22% over 7‑year‑period.[18‑20] However, increased 
detection rate for prostate cancer has not been convincingly 
linked to a reduction in mortality rate, although the recent 
report from the European Randomized study of Screening 
for Prostate Cancer (ERSPC) showed a 20% reduction in 
mortality rate.[19] However, this report was contradicted by 
the result of a similar study, the Prostate, Lung, Colo‑rectal 
and Ovarian Cancer Screening trial (PLCO trial) in the 
USA, which reported no significant reduction in prostate 
cancer‑specific mortality (PCSM) due to PSA screening.[20] 
The controversies on PSA testing revolve around the cut‑off 
point, diagnostic sensitivity and specificity, correlation with 
prostate cancer progression, pathological grade (Gleason 
score, GS) and tumour stage, and prediction of treatment 
response. In contrast, the benefits of PSA testing rely on 
its cost‑effectiveness, analytical reliability, frontline mass 
screening utility, high throughput, and to a certain extent 
its tissue specificity. In some developing countries, with poor 
access to urology services, PSA testing by ELISA method 
may not be readily available and/or affordable. In such cases, 
many laboratories resort to using immunochromatographic 
assays (strips) which are not reliable. This review summarizes 
the situation with respect to PSA testing and examines a 
battery of laboratory tests which have been developed in 
attempt to improve screening, diagnosis, and monitoring of 
prostate cancer treatment.
The pitfalls of prostate specific antigen testing
There is a controversy on exact cut‑off level for accepting 
normal PSA. The European Association of Urology 
guidelines on prostate cancer recommend <2.5‑3.0 ng/ml 
especially for younger men (<50 years of age).[21] In many 
countries including Nigeria, the 4.0 ng/ml cut‑off point is 
commonly used, giving a diagnostic sensitivity and specificity 
of ~20% and 94%, respectively.[20] A retrospective study in 
Nigeria reported a PSA sensitivity of 99.2% on 133 cases 
of hospital patients diagnosed with PCa.[22] But the study, 
which had a small sample size, did not consider patients 
who had elevated PSA with no prostate cancer and patients 
with low PSA who had prostate cancer. However, in the 
USA, the adopted cut‑off value is 2.50 ng/ml indicating 
a reported sensitivity and specificity of 40.5% and 81.1%, 
respectively.[20] The reason for the controversy is that the 
diagnostic sensitivity and specificity of PSA testing vary 
inversely at any chosen cut‑off level [Table 1].[23] It is 
important to differentiate between diagnostic sensitivity 
and specificity of a test from its analytical sensitivity and 
specificity. Diagnostic sensitivity of PSA test is the ability 
of a raised serum/plasma PSA level above a cut‑off point 
to correctly indicate a positive prostate cancer/disease 
case (confirmed by histology report). The analytical 
sensitivity of PSA test is the ability of the assay to quantify 
the lowest amount or concentration of PSA in blood 
sample. On the other hand, the diagnostic specificity of 
the PSA test is the ability of “normal” serum/plasma PSA 
level to correctly indicate the absence of prostate cancer/
disease (also confirmed by histology report). The PSA 
test, determined by ELISA either manually or automated, 
has a good analytical sensitivity and specificity but poor 
diagnostic sensitivity and specificity for prostate cancer. 
Figure 1: Pre-treatment	prostate	specific	antigen	level	has	no	
prognostic value. Figure displays the PSA level in 139 prostate 
disease cases.[35] Although a small sample size, there was no 
significant	difference	in	PSA	level	in	BPH	cases	compared	to	
all Gleason scores (GS) in prostate carcinomas. And within the 
GS,	there	was	no	significant	difference	in	PSA	level	(P > 0.05, 
Kruskal–Wallis test). This group was nearly age-matched (there 
was	no	significant	difference	in	the	age	group)
Nna: Prostate specific antigen testing?
409Nigerian Journal of Clinical Practice • Oct-Dec 2013 • Vol 16 • Issue 4
Availability and affordability of diagnostic tests, in any 
country, depend largely on the healthcare management 
system. But these socio‑economic factors do not outweigh 
the importance of diagnostic reliability. Even if PSA testing 
is made free, its diagnostic utility is still questionable. The 
implication of this is that the PSA as a biomarker has a 
weak correlation with prostate malignancy. Despite the 
differences in cut‑off points, there are several reports of 
cases of prostate cancer in men with serum PSA between 
2.0 and 4.0 ng/ml.[24,25] Therefore, a low PSA level with 
urinary symptoms indicative of prostate problems will still 
require other tests to rule out prostate cancer. On the 
contrary, high serum levels of PSA are about 70% less likely 
to result in prostate cancer cases. Whether low or high, a 
normal or abnormal PSA co‑existing with urinary symptoms 
associated with prostate diseases will necessarily require 
further/additional tests including a repeat serum PSA after 
an interval, DRE, the PCA3 test, and eventually a prostate 
biopsy for histology. To improve the diagnostic value of 
PSA testing, several ratiometric modifications of the test 
have been attempted.[24,25] These include: Free to total 
PSA ratio, PSA velocity (PSAV), PSA density (PSAD), 
PSA doubling time, and PSA and the human glandular 
kallikrein 2 (hK2) product.
•	 	The	percentage	free	PSA	(PSA	ratio):	This	is	the	ratio	
of free‑to‑total PSA expressed in percentage. In routine 
clinical practice, a free PSA ratio of <20% in men with 
elevated total PSA levels (>3.0 ng/ml) is associated with 
a higher risk of PCa and facilitates the indication to 
perform a prostate biopsy.[21] A cut‑off point of 18% (free 
PSA ratio) was reported to increase sensitivity and 
specificity of PSA testing from 55% and 73% to 71% 
and 95%, respectively.[13]
•	 PSAV:	 This	 is	 the	 rate	 of	 change	 of	 PSA	 over	
time (expressed in ng/ml/year). A PSAV >0.75 ng/ml/yr 
is an indicator for prostate biopsy.[20] The PSA velocity 
was reported to improve sensitivity and specificity of 
PSA testing to >80%.[21]
•	 PSAD:	This	 is	 the	 quotient	 of	 total	 serum	PSA	by	
prostate volume. A value of  >0.13 is considered 
abnormal.[19]
•	 PSA	doubling	time:	Expressed	in	months,	this	is	another	
measure of PSA kinetics for the time it takes to reach 
twice the nadir concentration of PSA in blood. This 
is very useful in defining biochemical recurrence after 
primary treatment.[21]
•	 PSA	and	hK2	product:	The	product	of	percent	PSA	and	
hK2 has been shown to enhance the diagnostic value of 
PSA testing especially in men with total PSA 3.0 ng/ml 
or greater.[26]
Molecular and physiological forms of prostate 
specific antigen
PSA is a glycoprotein and its molecular mass varies depending 
on the analytical instrument used for its determination: Mass 
spectrometry, 28.5 kDa and gel electrophoresis, 30‑36 kDa. 
The difference results from the glycosylation patterns of an 
N‑linked oligosaccharide attached to asparagine 45.[27] It is 
mostly secreted by the prostatic epithelium and the epithelial 
lining of the periurethral glands. However, extra‑prostatic 
secretions of PSA from tissues such as the breast have also 
been reported.[28‑30] Normal prostatic epithelial cells produce 
more PSA glycoprotein than the malignant prostate tissues 
and PSA mRNA is also expressed at higher levels in benign 
tissue than in malignant prostatic tissues. It is believed 
that the PSA leaks into the blood stream as a result of 
deformations in the architecture of the prostate gland during 
trauma and/or disease.[28] Therefore, PSA is not an ideal 
tumour marker because it is not produced in higher quantities 
by tumour cells rather there is increased leakage into blood 
stream as a result of tumour development.
PSA is a member of a family of serine proteases called 
the human tissue kallikreins. Currently, the family has 15 
members that are structurally similar, hormonally‑regulated, 
and enzymatically have either chemotrypsin‑ or trypsin‑like 
activity. Their genes are tandemly localized on chromosome 
19q13.4.[29] The PSA gene is designated as KLK3 and is 
known to have 11 mRNA variants mainly from alternative 
splicing. Not all of these variants encode a mature PSA 
protein. The mature PSA (enzymatically active) has 237 
amino acid residues and is found in both seminal fluid (SF) 
and serum in inactive forms. Physico‑chemically, PSA exists 
in two states: Free and complex (PSA bound to certain 
plasma proteins), and in both states there can be a mixture 
of active and inactive forms. Inactivity of PSA results from 
clipping of its amino acid residues at different positions. 
The term total PSA refers to all immunodetectable PSA in 
serum/plasma including free and complex PSA.
There are five different complexes of PSA:[28,29]
•	 PSA‑ACT:	 This	 is	 PSA	 covalently	 bound	 to	
α1‑antichymotrypsin, and is the major immunologically 
detectable form of PSA complex in the serum/plasma.
•	 PSA‑MG:	 This	 is 	 PSA	 covalently	 bound	 to	
α2‑macroglobulin. It is not immunodetectable and 
thus it is often referred to as occult PSA.
Table 1: Sensitivity and specificity for prostate cancer 
by cut points of prostate‑specific antigen
Any cancer (n=1225) versus no cancer (n=1362)
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•	 PSA‑PCI:	This	is	PSA	covalently	bound	to	protein	C	
inhibitor; a minor component in SF, not detected in 
serum.
•	 PSA‑AT:	This	is	PSA	covalently	bound	to	α1‑antitrypsin 
and its trace components are found in serum.
•	 PSA‑IT:	This	 is	PSA	covalently	bound	to	 inter‑alpha	
trypsin inhibitor and its trace components are also found 
in serum.
Free PSA refers to all non‑complexed PSA, which may 
be proteolytically active or inactive in SF, but always 
inactive in serum. Biologically, the PSA helps to liquefy 
the seminal coagulum and enhance sperm cells motility.[19] 
The threshold of PSA in SF and serum/plasma varies. Large 
amounts of PSA (0.5‑1.0 mg/ml) are present in the SF; while 
the serum level depends on age and prostate volume. For 
men up to 50 years old, the serum level is usually below 
4.0 ng/ml. It can normally increase up to 6.5 ng/ml in men 
aged 70‑79 years.[31,32]
Prostate specific antigen and prostate cancer progression
When PSA was first identified in SF and later on in serum, 
it was thought to be wholly specific to the prostate and 
differentially expressed in normal, benign, and malignant 
prostate tissues.[20,21] It therefore became widely used 
for screening, diagnosis, and therapeutic monitoring of 
prostate diseases. Its lower thresholds are within a reliable 
quantifiable range using the widespread ELISA assays. This 
was further facilitated by the commercial availability of 
monoclonal anti‑PSA antibodies with little cross‑reactivity 
to other members of the homologous kallikrein family.[22] 
Even the detection of PSA in urine was also considered 
in clinical samples.[23] However, it later began to emerge 
that many cases of elevated PSA had negative prostate 
biopsy results. In fact, it was estimated that a positive PSA 
result “signifies that a patient has a 25% chance for prostate 
cancer, which therefore causes 75% of men to have unnecessary 
biopsies.”[24]
Part of the problem was that PSA testing had few 
randomized controlled clinical trials before it became 
widely entrenched in clinical use. In addition, DRE 
was used as the main supplement to the PSA test.[25] 
Subsequent clinical trials confirmed that the PSA test was 
superior to DRE in detecting PCa,[26] but the introduction, 
in some countries, of mass screening of older men (aged 
50 years and above) for prostate cancer using the PSA 
test prompted a wide debate on the diagnostic value of 
the test. In either mass screening or individual screening 
where individuals decide to know their PSA levels, the 
debate is centered on diagnostic reliability of the PSA test. 
The second part of the problem is that prostate cancer is 
primarily a disease of old age and many people die with the 
disease and not from the disease. Therefore, the benefit of 
using PSA to detect the disease early may not necessarily 
translate to better survival. In fact, it could result in 
over‑diagnosis and over‑treatment of prostate diseases. 
The PSA test also does little to predict the biological 
behaviour of prostate diseases.[33‑35]
Hence, the diagnostic, prognostic, and predictive values 
of the PSA test became questionable. In fact, a recent 
study showed a similar survival benefit for men who 
had “watchful waiting” in comparison with those who 
had radical prostatectomy.[27] The questionable value of 
PSA testing may stem from the heterogeneous nature of 
prostate cancer and its unpredictable natural course.[28,29] 
Not all histologically detectable prostate cancers are 
symptomatic (clinically important); and some do not even 
require treatment. Overall, it becomes apparent that PSA 
testing has a limited value in prostate cancer management; 
it has been enormously over‑used, but its use has continued 
because there was no other affordable, reliable, and flexibly 
high throughput screening test to replace it. Lately, it 
has been postulated that serum PSA correlates better to 
progression of benign nodular hyperplasia (BPH) than 
PCa, merely from the fact that in most cases there are 
always many benign lesions around small foci of prostate 
cancers in a biopsy.[30] Because of the weak correlation 
with prostate malignancy (and perhaps a better correlation 
with benign nodular hyperplasia), the PSA test is always 
inconclusive in both high and low levels. Consequently, 
the value of having a test in which a low or a high value 
does not necessarily affirm a positive case rather triggers 
a cascade of investigations that are often traumatic, 
expensive, and time‑consuming irrespective of its outcome 
is the contention of many medical practitioners who fail to 
recommend PSA test. This does not negate the fact that 
there has been a significant increase in early detection of 
PCa through PSA testing, but the benefits of such early 
detections have also been controversial in the debate for 
a mass screening programme and/or individual screening.
The analytical strength of prostate specific antigen 
testing
As mentioned earlier, the analytical sensitivity and specificity 
of PSA testing are very reliable. There are both automated and 
manual systems to conduct PSA ELISA tests accurately using 
either spectrophotometric or immunofluorometric procedures. 
The test is generally cheap, flexibly high throughput, and 
minimally invasive (venepuncture). The PSA ELISA test is 
never more expensive than routine hormonal assays. Other 
novel test methods for PSA that could be amenable to point 
of care testing include electrochemical detection, optical 
biosensing, and mass sensitive detection.[31] Unfortunately, the 
detection limits of these newer methods are not yet comparable 
to those of ELISAs. The availability of commercial anti‑PSA 
antibodies and pure PSA antigens is also facilitating the 
progress in the development of other forms of immunometric 
assays. Some studies have shown that urine PSA level is 
not clinically useful in early detection and monitoring of 
prostate cancer.[23,36‑40] Other studies have also shown that 
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the PSA transcript numbers (copies of mRNA) in blood 
and urine samples are also not clinically useful for prostate 
cancer detection.[32,41‑45] Therefore, the ELISA remains the 
main technique for PSA testing. However, qualitative lateral 
flow assays (based on paper chromatography) have also been 
developed. Such assays are designed to show <4.0 ng/ml, 10 ng/
ml, and >10 ng/ml points as colour bands and could prove 
useful though not reliable in developing countries without 
basic facilities for ELISA.
Mass screening for early detection of prostate cancer
The idea of using either PSA test or DRE or both to identify 
an early stage of prostate cancer has been a huge debate in 
the public health domain. An extensive review of the pros 
and cons of the debate is contained in a WHO paper.[25] 
The reports of the long‑awaited European Randomized 
Study of Screening for Prostate Cancer (ERSPC) and the 
USA Prostate, Lung, Colorectal, and Ovarian (PLCO) 
clinical trials have not helped matters.[33] The ERSPC 
trial showed a 20% reduction in prostate cancer specific 
mortality (PCSM) as a result of early detection by mass 
screening. However, the PLCO trial showed no significant 
reduction in PCSM as a result of early detection by mass 
screening. In both trials, PSA testing was the frontline 
test, followed by DRE and prostate biopsy (for those with 
elevated PSA). The salient fact is that PSA is a weak 
biomarker which cannot predict the biological behaviour 
of prostate cancer. The problems of over‑diagnosis and 
over‑treatment come from the fact that there are currently 
no validated biomarkers that can differentiate aggressive 
from non‑aggressive PCa in all cases of indolent prostate 
cancers detected by PSA testing.[33‑35,46‑49] Although early 
detection of any form of disease is still a safer option to 
adopt whether by mass screening or individual clinical 
consultation, commencement and choice of treatment 
depend on the aggressive behaviour of the disease and the 
patient’s choice. In the case of prostate cancer, a biomarker 
other than the PSA is required for mass screening to assist 
in identifying lethal forms of the disease.
Alternatives/supplementaries to prostate specific 
antigen testing
Several other prostate cancer biomarkers have been 
reported, which include: PCA3, sarcosine, transmembrane 
serine protease 2 fusion genes (TMPRSS2: ETS 
genes etc.,), cluster of differentiation 44 (CD44), 
glutathione‑S‑transferase P1 (GSTP‑1), alpha methlyacyl 
coenzyme A racemase (AMACR), human epidermal 
growth factor receptor 2 (HER‑2/Neu), enhancer of 
Zeste homolog (EZH2/histone methyl transferase); early 
prostate cell antigens 1 and 2, prostate‑specific membrane 
antigen (PSMA), prostate stem cell antigen (PSCA), and 
ribonuclease L (RNASEL).[33‑35,46‑49] The list of putative 
prostate biomarkers is growing rapidly, but few have been 
validated in larger sample studies. Reports of the evaluation 
of some of these biomarkers have not been consistent partly 
due to lack of validation of diagnostic technologies. Many 
of these markers previously tested using proteomic assays 
can now be tested using molecular techniques including 
real‑time PCR, which enables very sensitive, accurate, 
and rapid quantitation of these markers in tissue sections, 
exfoliated urine cells, and circulating cells in blood.[35,50‑51] 
Combining some of these known markers in a single test 
using minimally invasive sample collection methods such 
as urine cell sediments after attentive DRE and/or serum is 
a potential approach for clinical diagnosis and monitoring 
of prostate cancer in the post‑PSA era. In addition, these 
putative biomarkers can also be evaluated for prognosis 
following primary treatment of PCa using high throughput 
techniques such as high‑density tissue microarrays on 
prostate biopsies as well as real‑time PCR techniques on 
both biopsies and urine cell sediments.[35]
Prostate cancer antigen 3
This was first described by Bussemakers and colleagues in 
1999. PCA3 gene formerly known as differential display 3 
(DD3) gene is localized at chromosome 9q21 and encodes 
a prostate‑specific RNA that is highly overexpressed 
in PCa tissue compared with benign prostatic tissue.[3] 
The PCA3 does not encode a known protein product, 
suggesting that the RNA may play a regulatory role in 
prostate tumourigenesis. Its possible use as a urinary marker 
for PCa was suggested by de Kok et al. in 2002.[2] The 
clinical assay for PCA3, a real‑time PCR, was developed 
in the Nijmegen laboratory, the Netherlands; and results 
of controlled clinical trials in Canada and Austria have 
confirmed the potential use of the assay for PCa diagnosis.[2] 
Following the acquisition of patent right from nijmegen 
by Diagno cure company and later by gen‑probe USA, a 
new quantitative molecular test based on target capture, 
transcription‑mediated amplification, and hybridization 
protection, PCA3 received its CE mark in 2008 and it is 
now used in many clinical laboratories in Europe.[11,36,52]
Biologically, the median upregulation of PCA3 transcript 
from normal to tumour tissue was reported as 34‑fold, 
increasing to 66‑fold in tumour tissues containing more than 
10% cancer cells.[37] Although the biological function of the 
PCA3 is unknown, its upregulation in prostate cancer tissues 
provided a basis for detecting the presence of the gene in 
tissues containing only a small number of prostate cancer 
cells against a background of low expression by many normal 
or BPH prostate cells in tissue biopsies and urine. Thus, the 
importance of denoting PCA3 as a ratio with PSA mRNA 
(a surrogate for background prostate epithelial cell nuclear 
material) was established.[37] Equally important, a practical 
application was confirmed: The PCA3 ratio determined 
in voided urine, especially after light prostatic massage, 
or “attentive” DRE has been shown to be a sensitive and 
specific test for PCa.[4,11,38,52‑55] The validity of the assay 
depends very largely on informative specimen, that is, 
specimen with sufficient prostatic nuclear material measured 
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by PSA mRNA. The result of the assay is expressed as a 
score (PCA3 score) = (PCA3 mRNA/PSA mRNA) × 1000.
The diagnostic reliability of the PCA3 score has been 
evaluated in several studies.[36,37] Marks et al. 2007 reported 
a sensitivity of 58% and specificity of 72% at the commonly 
accepted cut‑off score of 35.[36] Their report also showed an 
inter‑run variation (precision) of about 20%. Rubrio‑Briones 
et al. in 2011 reported using receiver operator curve (ROC) 
analysis an area under the curve (AUC) for PSA and PCA3 
of 0.532 (P = 0.417) and 0.672 (P < 0.0001), respectively; 
sensitivities of PSA ≥ 4 ng/ml and PCA3 ≥ 35 were 87% 
versus 85%, with specificities of 12% versus 33%, positive 
predictive value (PPV) 34% versus 39% and negative 
predictive value (NPV) 63% versus 81%, respectively. 
The PCA3 score showed direct correlation with the 
percentage of positive biopsies (P < 0.0001).[56] The PCA3 
score of 35 means 35 mRNA copies of PCA3 per one copy 
of PSA mRNA. Fradet et al. (2004)[38] reported a sensitivity 
of 50% and specificity of 76% at the PCA3 cut‑off score of 
35, with an AUC of 0.68 compared to AUC of 0.54 for PSA 
test. A recent study in South Africa has shown that a PCA3 
score (threshold) of 60 is more discriminatory (detects more 
positive cases) than the conventional score of 35.[52] Several 
studies have shown that the performance characteristics 
and diagnostic reliability of PCA3, based on sensitivity, 
specificity, PPV, NPV, accuracy, biopsy outcome, and AUC 
are superior to those of the PSA.[3,4,13,52,54,56‑58] The PCA3 test 
is therefore judged clinically superior to PSA test. However, 
there are no reported clinical trials on reduction of PCSM 
due to PCA3 testing.
A particularly important role of the PCA3 test appears 
to be in men with persistently elevated serum PSA 
levels (>2.50 ng/ml), but a negative initial biopsy.[59] In such 
men, who constitute a large problematic group, the odds 
ratio for the PCA3 test to predict cancer upon re‑biopsy 
is 3.6, compared to only 1.2 for serum PSA testing.[37] 
However, at the cut‑off point of 35, the PCA3 could only 
predict a 30% positive biopsy, increasing to 50% at PCA3 
score of 100.
Currently, there is no clear‑cut evidence that PCA3 score 
correlates strongly with GS (tumour grade) although some 
studies have reported a significantly lower PCA3 score 
in GS <7 compared to those ≥ 7.[60‑64] Molecular grading 
would be invaluable in predicting the clinical outcome of 
intermediate GS tumors (scores: 6‑7). There is also the 
inverse relationship between sensitivity and specificity of 
the PCA3 score, much similar to that of PSA. At lower 
cut‑off points, the sensitivity increases as the specificity 
drops [Table 2] compared to Table 1 for PSA. However, the 
factors that skew PSA results such as trauma, 5α‑reductase 
inhibitors (finasteride and dutasteride), prostatic volume, 
age, inflammation, and DRE do not affect PCA3 score.[36] 
PCA3 score before radical prostatectomy is known to 
predict extra‑capsular extension and tumour volume[65] as 
well as multi‑focality.[66] The difficulty in correlating PCA3 
score with prognostic and predictive markers of prostate 
cancer is also related to the heterogeneous natural course 
of the disease. Even a higher GS does not necessarily imply 
aggressiveness.[33‑35,49,67] There is no available information 
on ethnic variations of PCA3 score, if any. The test uses 
20‑30 ml of first catch urine after prostatic massage 
(2‑3 massages) or attentive DRE. Without prostatic 
massage, the number of exfoliated cells is drastically 
reduced. There are possibilities that the PCA3 test can be 
improved by addition of other tests such as the TMPRSS2: 
ETS gene‑fusion and KLK2 (hK2). Another important 
factor is that the regulation of the PCA3 gene is not clearly 
defined. The nucleotide sequence for the PCA3 RNA has 
several single nucleotide polymorphisms (SNPs), more than 
100 identified SNPs (using the UCSC Genome browser). 
More studies are still required to define the biological role of 
this non‑coding RNA. The PCA3 is available and affordable 
in most developing countries depending on their healthcare 
management system.
Sarcosine urine test
A report in the journal, Nature,[1] created a huge expectation 
of a new test “the Sarcosine urine test.” Currently, there are 
no reports of successful repeat studies on the sarcosine 
marker in prostate cancer.[68‑71] Therefore, it is still too 
early to speculate on the diagnostic value of this new 
test. The method of sarcosine detection and quantitation 
would require further simplification than it was in the 
original report and subsequent studies.[72‑74] However, the 
involvement of sarcosine in the intermediary metabolic 
pathways that are strongly associated with prostate 
cancer metastasis could be of prognostic and predictive 
significance.[75‑80] Much work is still required to translate 
the sarcosine test to clinical use. The sarcosine urine test, 
unlike the PCA3 test, is still controversial[69,81,82] and requires 
more randomized controlled clinical trials and simplified 
reproducible methods of analysis.
Other molecular test
Many other molecular markers [Tables 3‑5] such as the 
ETS transcription factor fusion genes with TMPRSS2 and 
other 5’ partners such ERG genes have been well described 
elsewhere[39‑41] and these markers are considered for inclusion 
in a multiplex testing format for a more sensitive and specific 
diagnosis of prostate cancer. The TMPRSS2 fusion genes 
Table 2: Sensitivity and specificity of the prostate 
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Table 3: Summary of molecular makers of prostate cancer
Gene/protein Biological role and potential use
AKT and PTEN Prostate‑specific phosphatase and tensin homologue (PTEN) loss of function induces AKT (protein kinase) 
inhibiting apoptosis and may cause tubule regeneration with prostatic intraepithelial neoplasia (PIN)
Use: Prognostic and therapeutic
AMACR Alpha methlyacyl coenzyme A racemase protein voided in urine. Involved in fatty acid β‑oxidation. 
Androgen‑independent function as promoter of PCa
Use: Diagnostic
AR Androgen receptor, nuclear transcription factor mediates steroid hormones and stromal cell growth. AR activation 
in luminal cells suppresses growth
Use: Prognostic and therapeutic
Bcl‑2 B‑cell CLL/lymphoma 2, anti‑apoptotic protein found in basal cells and stem cells.[2] Loss of expression linked to 
PIN, progression and androgen independence
Use: Prognostic and therapeutic
BRCA2 Breast cancer type 2 susceptibility protein, tumor suppressor gene, predisposes to Pca, chromosome 13q.
Use: Prevention
CD44 Cluster differentiation 44. Transcript variants of CD44 are associated with PCa progression and metastasis.
Use: Prognostic
CgA Chorionic gonadotropin alpha, neuroendocrine pre‑hormone peptide. Unclear mechanism of action.
Use: Prognostic
Cyclin D1 Role in cell cycle from G1‑to S‑phase
Use: Prognostic
E‑cadherin Cell adhesion molecule. Downregulation/loss associated with invasion and metastasis
Use: Prognostic
EGFR (Erb B1) Her‑2/Neu (Erb 2) Activation associated with proliferation, malignant transformation, relapse, progression, and androgen 
independence. Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2
Use: Prognostic and therapeutic
EN‑2 Mouse engrailed‑2 gene. Homoeobox‑containing transcription factor/candidate oncogene, overexpressed in 
aggressive HRPC/PCa. May be positively modulated by PAX2
Use: Diagnostic and prognostic
PCa=Prostate cancer
Table 4: Summary of molecular makers of prostate cancer contd
EPCA 1 and 2 Early prostate cell antigen, nuclear matrix protein. Associated with proliferative inflammatory atrophy (PIA), PIN, and PCa. Generally, 
not‑detected in non‑cancer cases
Use: Diagnostic and prognostic
ER
EZH2
Oestrogen receptor located in stromal. Role unclear. Enhancer of Zeste homolog (EZH2), histone methyl transferase upregulation.
Use: Prognostic
GSTP‑1 Glutathione‑S‑transferase P1 protects DNA from free radicals (caretaker gene). Loss of gene expression due to hypermethylation 
associated with prostate cancer
Use: Diagnostic
IL‑6 Interleukin‑6: Cytokine immunomodulator. Linked to AR cells and suppression of androgen‑dependent cells.
Use: Prognostic
KLK3/PSA Encodes PSA, a kallikrein‑related peptidase (serine protease subgroup) on chromosome.
Use: Prognostic and therapeutic
KLK2/hK2 Encodes hK2, a kalikrein‑related peptidase (serine protease subgroup) on chromosome. Serum levels 1% of PSA and undetectable in 
healthy males
Use: Diagnostic and prognostic
MIB‑1 Mindbomb homolog 1, monoclonal antibody and cell proliferation marker by Ki‑67 antigen recognition.
Use: Prognostic
MSMB Microseminoprotein beta‑, encodes PSP94, immunoglobulin‑binding factor synthesized in prostatic epithelial cells.
Use: Prognostic
NKX3.1 NK3 transcription factor related, locus 1, homoeobox tumour suppressor gene, exclusive to prostate, undergoes epigenic inactivation
Use: Prognostic
NSE Neuron‑specific enolase, neuroendocrine cell product
Use: Prognostic
PCa=Prostate cancer; hK2=Human glandular kallikrein 2; PSA=Prostate‑specific antigen; EPCA: Early prostate cell antigen; PIN=Prostatic intraepithelial 
neoplasia; DNA=Deoxyribonucleic acid; AR=Androgen receptor
Nna: Prostate specific antigen testing?
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occur specifically in prostate diseases, mostly in prostate 
cancers.[83‑85] They are also detectable in exfoliated urine 
cells.[86,87] Expression of TMPRSS2 fusion genes in prostate 
cancer predicts unfavourable prognosis and correlates well 
with morphological features.[88,89] There are now attempts to 
combine TMPRSS2‑ETV and TMPRSS3‑ERG fusion genes 
and PCA3 in multiplex assay formats, such as real‑time PCR, 
using samples of exfoliated urine cells.[90,91] These attempts 
reflect the heterogeneous nature of prostate cancer and the 
inadequacy of a single tumour marker for effective screening, 
grading, and monitoring of treatment.
Another consideration is the CD44 transcript variants in 
prostate cancer progression.[42] Some variants of CD44 
especially isoforms 3 are known to predict PSA relapse, 
correlate with GS and pathological grades.[92‑94] It is possible 
that such molecular characterization of prostate diseases may 
reduce the frequency of prostate biopsies and also influence 
the decision‑making process for treatment. The GSTP‑1 
gene has been strongly associated with PCa progression 
and its testing in a panel of four genes was shown to yield 
a very high sensitivity and specificity (87% and 100%, 
respectively) for prostate cancer.[95‑99] It is another potential 
marker for PCa screening. The histone methyltransferase 
EZH2 gene is reported to show over‑expression in metastatic 
PCa, and this corroborates with increased amino acid 
metabolism and methylation associated with prostate cancer 
progression.[1,75] The expression of the EZH2 gene also 
correlates with sarcosine expression in prostate samples.[1] 
Multiplex assay formats can provide additional information 
on molecular characteristics of prostate diseases. Many 
of these tumour markers, shown in Table 3, have been 
known for a considerably longer time but due to lack of 
validated commercial assays, they have not been clinically 
evaluated.[100]
Summary
In the near future, it is likely that more laboratory tests 
will increasingly be introduced for clinical diagnosis of 
prostate diseases. A typical request form for prostate profile 
may include PSA, hK2, and GSTP‑1 blood tests; PCA3, 
TMPRSS2‑ETS, and sarcosine urine tests. In addition, 
molecular tests aimed at molecular grading of prostate 
cancer using exfoliated urine cells from prostate massage will 
also help to reduce request for prostate biopsy and improve 
risk stratification of patients. The TMPRSS‑ETV/‑ERG 
fusion transcripts can now be tested on the same urine 
Table 5: Summary of molecular makers of prostate cancer contd
p27Kip1 Cell cycle inhibitor found in basal compartment. Chromosome 12p12–13.1
Use: Prognostic and therapeutic
PAP Prostate acid phosphatase, glycoprotein more specific to prostatic tissue than PSA
Use: Diagnostic and therapeutic
PCA3 (DD3) Prostate cancer antigen 3. Chromosome 9, messenger RNA overexpressed in>95% PCa and metastases. Detected by reverse 
transcriptase on urine sediment. PROGENSA™ PCA3 Assay available
Use: Diagnostic
PSMA Prostate‑specific membrane antigen. Androgen‑independent prostatic epithelium transmembrane protein found in PCa/lymph 
node metastasis
Use: Prognostic and therapeutic
PSCA Prostate stem cell antigen. Membrane glycoprotein. Normal late‑intermediate prostate cell marker upregulated in PCa.
Use: Prognostic
p53 Tumor suppressor gene allows DNA repair/cell apoptosis in cellular stress conditions
Use: Prognostic and therapeutic
RNASEL Ribonuclease L (2′,5′‑oligoisoadenylate synthetase‑dependent). Candidate tumor suppressor gene product[42] implicated in viral 
defense regulates cell proliferation and apoptosis via an interferon pathway Ch 1q23‑25
Use: Diagnostic
TGF‑b1 Transforming growth factor. Pleiotrophic growth factor known to promote stem cell quiescence
Use: Prognostic
TMPRSS2: ETS Transmembrane protease, serine 2 fusion gene (Ch 21), upregulates ETS target genes controlling cell proliferation, differentiation, 
apoptosis, and transformation
Use: Prognostic and Prevention
Sarcosine Sarcosine, an N‑methyl derivative of the amino acid glycine was shown to have a very strong correlation with prostate cancer 
progression
Use: Diagnostic
Sex hormones and 
binding globulin
Testosterone is essential for prostatic development and maintenance. Oestrogens are associated with low risk of PCa
Use: Prognostic and prevention
u‑PA/u‑PAR Urokinase plasminogen activator/cell surface receptor. Role in basement membrane/extracellular matrix degradation and 
metastases
Use: Prognostic
PSA=Prostate‑specific antigen; PCa=Prostate cancer; DD3=Differential display 3; PAP=Prostate acid phosphatase; RNA= Ribonucleic acid
Nna: Prostate specific antigen testing?
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samples for PCA3 tests using real‑time PCR, which has 
a very flexible high throughput and analytical reliability. 
Such multiplex molecular testing may predict aggressiveness 
and lethality of PCa and inform better treatment choice 
than PSA testing. Prostate cancer will soon lend itself 
to better molecular characterization in exfoliated urine 
cells (minimally non‑invasive).
There are also likely to be introduction of clinical genetic 
tests to assess risk of PCa development using genetic 
variations such as SNP, copy number variations, and 
hypermethylation status of some genes. This can also be 
done using the exfoliated urine cells from prostatic massage. 
Despite these developments, PSA testing is likely to remain 
in clinical routine screening due to availability, affordability, 
and familiarity but will largely be supplemented by newer 
molecular tests.
Conclusion
PSA testing may diminish in future to allow for a more 
multiplex analytes’ testing for improved diagnostic sensitivity 
and specificity as well as better molecular characterization 
of biological and clinical behaviour of prostate cancer to 
inform a better treatment/prevention strategy. The current 
diagnostic strategy is unduly over‑dependent on PSA 
testing, which has generated problematic over‑diagnosis 
and over‑treatment. Newer tests can assist to molecularly 
define prostate diseases, facilitating clinical discrimination 
of aggressive PCa from non‑aggressive indolent PCa. It is 
therefore necessary that commercial assays such as PCA3 
test be expanded into multiplex formats to include more 
reliable tumour markers, for example the GSTP‑1 and 
TMPRSS2: ETS and EZH2 genes, and that such assays 
can serve for mass screening and individual clinical testing. 
The potential for combined testing of biomarkers using 
minimally invasive methods of sample collection such as 
exfoliated urine cells following DRE and/or venepuncture 
is to reduce unnecessary prostate biopsies and also identify 
clinically important PCa during screening. These benefits, 
which supersede those of PSA testing, will also, be required 
to yield a significant reduction in PCSM rate so as to justify 
early detection.
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